Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Rise on 'Buy' Rating

NEW YORK (GenomeWeb News) – Shares of Sequenom rose 17.6 percent to close at $5.95 in Thursday trade on the Nasdaq after Cantor Fitzgerald initiated coverage of the firm with a “buy” rating.
 
Cantor Fitzgerald also placed a $12 price target on Sequenom’s shares and expects the firm to become profitable in 2010. The Cantor Fitzgerald analyst cited the revenue growth potential of Sequenom’s MassArray system.
 
Last month, Sequenom posted fourth-quarter 2007 revenue growth of 41 percent to $11.1 million, while its net loss climbed 28 percent to $6.8 million.
 
 

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.